Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

NCT01032395 is registered in ClinicalTrials.gov with Chiltern Pesquisa Clinica Ltda as lead sponsor.

NCT NCT01032395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01032395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
Lead sponsor
Chiltern Pesquisa Clinica Ltda
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
August 31, 2012
Enrollment
342 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart disease, chronic pulmonary disease, diabetes mellitus, h1n1 influenza virus